The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...
The study explores whether denosumab, a widely used therapy for osteoporosis and bone tumors, can regenerate beta cells, ...
Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...
On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...
Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...
Currently, Amneal commercializes three biosimilars in the U.S., with the two denosumab biosimilar candidates representing its next potential biosimilar launches. Additionally, three more ...
On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...
The FDA approved denosumab-bmwo for all indications of the reference drugs Prolia and Xgeva. According to a settlement between Amgen and Celltrion, the biosimilars can be launched as early as June 1.
The US Food and Drug Administration (FDA) has approved Celltrion’s biosimilars referencing Amgen’s bone disease therapy denosumab. The regulator has approved Stoboclo (CT-P41, denosumab-bmwo) and ...
During the trial, scientists from City of Hope ® will assess if people with early type 1 diabetes can protect and preserve ...
Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback